Cited by 844Antifungal resistance and susceptibilityFungal Infections and StudiesFungal and yeast genetics research

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M. +1 more·2002·Clinical Infectious Diseases

Abstract

To evaluate the efficacy and safety of voriconazole in acute invasive aspergillosis (IA), an open, noncomparative multicenter study was conducted. Immunocompromised patients with IA were treated with intravenously administered voriconazole 6 mg/kg twice a day (b.i.d.) twice and then 3 mg/kg b.i.d. for 6-27 days, followed by 200 mg b.i.d. administered orally for up to 24 weeks. Response was assessed by clinical and radiographic change. A total of 116 patients were assessable. IA was proven in 48 (41%) and probable in 68 patients. Voriconazole was given as primary therapy in 60 (52%). Good responses were seen in 56 (48%); 16 (14%) showed complete response and 40 (34%) partial response. A stable response was seen in 24 patients (21%), and 36 (31%) of the infections failed to respond to therapy. Good responses were seen in 60% of those with pulmonary or tracheobronchial IA (n=84), 16% with cerebral IA (n=19), 58% with hematologic disorders (n=67), and 26% of allogeneic stem cell transplant recipients (n=23). Voriconazole is efficacious in treating acute IA.

Integrity signals

Registry

Crossref · 10.1086/324620

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment success in retrospective analyses has been associated with voriconazole serum trough concentrations of 1 to 2 mg/mL.

    “Treatment success in these retrospective analyses has been associated with serum trough concentrations of 1 to 2 mg/mL.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H.
Affiliations
  • North Manchester General Hospital (GB)
  • Hôpital Saint-Louis (FR)
  • CHU Dijon Bourgogne (FR)
  • Hôpital d'Hautepierre (FR)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Denning, D. W.
Venue
Clinical Infectious Diseases
Published
2002-03-01
Volume
34
Issue
5
Pages
563-571
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W1964720826
Cited by
844
References
45
Citations by year
2026: 7 · 2025: 9 · 2024: 15 · 2023: 13 · 2022: 20 · 2021: 19 · 2020: 17 · 2019: 24 · 2018: 16 · 2017: 25 · 2016: 28 · 2015: 22 · 2014: 24 · 2013: 36 · 2012: 37
FWCI
43.61
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
voriconazole, invasive aspergillosis, antifungal therapy, immunocompromised patients, treatment efficacy, drug safety, pulmonary aspergillosis, cerebral aspergillosis, hematologic malignancies
MeSH terms
Acute Disease, Administration, Oral, Adolescent, Adult, Aged, Antifungal Agents, Aspergillosis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Pyrimidines, Triazoles, Treatment Outcome, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review